DanaherDanaher (NYSE:DHR) shares dipped slightly today on first-quarter results that came in ahead of the consensus forecast.

The Washington, D.C.-based company posted profits of $1.7 billion, or $2.31 per share, on sales of $7.7 billion for the three months ended April 1, 2022, for a 1.3% bottom-line gain on sales growth of 12.1%.

Adjusted to exclude one-time items, earnings per share were $2.76, 10¢ ahead of Wall Street, where analysts were looking for sales of $7.5 billion.

“We had a good start to the year with results exceeding our initial expectations,” Danaher President and CEO Rainer M. Blair said in a news release. “Our team successfully navigated a dynamic environment to deliver double-digit core revenue growth, approximately 10% adjusted earnings per share growth and $2.0 billion of operating cash flow, despite difficult prior-year comparisons.

“This performance was broad-based with all three of our segments delivering high-single-digit or better core revenue growth. We believe our strong execution combined with investments in innovation have driven market share gains in many of our businesses.”

Danaher projects revenue growth for the full 2022 year to fall in the high-single-digit percent range.

DHR shares were down 0.5% at $278.85 as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.4%.